Free Trial
NASDAQ:ALLR

Allarity Therapeutics 8/5/2024 Earnings Report

Allarity Therapeutics logo
$1.11 -0.06 (-5.13%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.08 -0.03 (-2.25%)
As of 06:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allarity Therapeutics EPS Results

Actual EPS
-$3.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Allarity Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Allarity Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Allarity Therapeutics' next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

Conference Call Resources

Allarity Therapeutics Earnings Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Allarity Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Allarity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Allarity Therapeutics and other key companies, straight to your email.

About Allarity Therapeutics

Allarity Therapeutics (NASDAQ:ALLR), a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

View Allarity Therapeutics Profile

More Earnings Resources from MarketBeat